Phase 2b Biomarker Analysis: BCMA CAR-T in Myasthenia Gravis
Episode Summary
BCMA-directed CAR-T therapy shows promise in myasthenia gravis by selectively targeting plasma cells, improving outcomes, and prompting biomarker-guided care, outpatient delivery models, and health system adaptation.